Tenaya Therapeutics awarded Chief Medical Officer Tingley Whittemore 49,000 shares at $0 per share on September 10, 2026. The award left Whittemore with 263,073 shares, while a separate grant covered 293,000 derivative securities. Investors have specific visibility into the executive’s resulting holdings and the award’s zero-cost terms.

Key Highlights

  • Tingley Whittemore received 293,000 derivative securities in a separate award on September 10, 2026.
  • The share award represented about 18.6% of Whittemore’s resulting shareholding.
  • The transaction carried code A, which denotes an award or grant.

Tenaya Therapeutics, Inc. (NASDAQ: TNYA) awarded Chief Medical Officer Tingley Whittemore 49,000 shares at $0 per share on September 10, 2026. Whittemore’s resulting holding stood at 263,073 shares. The same date also brought an award of 293,000 derivative securities, leaving Whittemore with 293,000 derivative securities after the transaction. The filing reported the awards under transaction code A.

Share Award Details

The 49,000-share grant represented about 18.6% of Whittemore’s resulting shares holding. The derivative securities award represented about 100.0% of the resulting derivative securities holding. The filing reported the awards under transaction code A. The share award had a stated price of $0 per share, while the derivative securities award was recorded separately from the 49,000 shares. Whittemore serves as Tenaya Therapeutics’ Chief Medical Officer. The resulting holdings reported after the awards were 263,073 shares and 293,000 derivative securities. Transaction code A denotes an award, grant, or other Acquisition from the company.